Candel therapeutics to host non-small cell lung cancer (nsclc) r&d breakfast panel during 2024 asco annual meeting

Management and scientific/medical thought leaders to discuss topline overall survival data from phase 2 clinical trial of can-2409 in nsclc management and scientific/medical thought leaders to discuss topline overall survival data from phase 2 clinical trial of can-2409 in nsclc
CADL Ratings Summary
CADL Quant Ranking